OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CV$7.2558

CapsoVision Inc

Advanced Medical Equipment & TechnologyVerified

CapsoVision operates with a debt-free capital structure, as evidenced by a zero debt-to-equity ratio and no long-term debt obligations. The company maintains a strong liquidity position with a current ratio of 3.77, indicating sufficient short-term assets to cover liabilities. However, the company's liquidity is constrained by negative operating and free cash flows of -$22.86 million and -$25.19 million, respectively, which suggest ongoing cash burn. Profitability metrics reveal significant underperformance relative to industry norms. The company reported a net loss of $25.32 million and an operating loss of $25.52 million, resulting in negative returns on equity (-190.91%) and assets (-139.37%). These figures indicate a company in operational distress, with no clear path to positive earnings in the near term. Geographically and segment-wise, CapsoVision's revenue concentration is not disclosed in the available data, but the absence of segment-specific financials suggests a lack of diversification risk management. The company's business model appears to be concentrated in a single product line or market, which increases vulnerability to market-specific shocks. Looking ahead, the company's growth trajectory is uncertain. The absence of revenue growth data and the continued negative cash flows suggest a lack of momentum. Analysts have assigned a mean price target of $10.50, implying a potential upside of 45% from the current market price of $7.25. However, the lack of buy or strong-buy recommendations (only two "buy" ratings) indicates limited institutional confidence in the company's near-term prospects. Risk factors include the company's ongoing losses and negative cash flows, which could necessitate additional financing. The risk assessment indicates low dilution risk, but the absence of disclosed dilution sources does not eliminate the possibility of future equity raises. The company's valuation is highly speculative, with a price-to-book ratio of 27.26, which is significantly elevated and not supported by positive earnings or cash flows. Recent events include the publication of the latest financial data, which confirms the company's continued losses and negative cash flows. No material filings or transcripts have been disclosed that would suggest a strategic pivot or significant operational change.

30-day price · CV(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyCapsoVision Inc
TickerCV.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. CapsoVision Inc develops and commercializes advanced medical imaging and diagnostic technologies, primarily focused on endoscopic visualization systems for minimally invasive surgical procedures.

Classification. CapsoVision is classified in the Healthcare sector under the Advanced Medical Equipment & Technology industry with 92% confidence based on verified market data.

CapsoVision operates with a debt-free capital structure, as evidenced by a zero debt-to-equity ratio and no long-term debt obligations. The company maintains a strong liquidity position with a current ratio of 3.77, indicating sufficient short-term assets to cover liabilities. However, the company's liquidity is constrained by negative operating and free cash flows of -$22.86 million and -$25.19 million, respectively, which suggest ongoing cash burn. Profitability metrics reveal significant underperformance relative to industry norms. The company reported a net loss of $25.32 million and an operating loss of $25.52 million, resulting in negative returns on equity (-190.91%) and assets (-139.37%). These figures indicate a company in operational distress, with no clear path to positive earnings in the near term. Geographically and segment-wise, CapsoVision's revenue concentration is not disclosed in the available data, but the absence of segment-specific financials suggests a lack of diversification risk management. The company's business model appears to be concentrated in a single product line or market, which increases vulnerability to market-specific shocks. Looking ahead, the company's growth trajectory is uncertain. The absence of revenue growth data and the continued negative cash flows suggest a lack of momentum. Analysts have assigned a mean price target of $10.50, implying a potential upside of 45% from the current market price of $7.25. However, the lack of buy or strong-buy recommendations (only two "buy" ratings) indicates limited institutional confidence in the company's near-term prospects. Risk factors include the company's ongoing losses and negative cash flows, which could necessitate additional financing. The risk assessment indicates low dilution risk, but the absence of disclosed dilution sources does not eliminate the possibility of future equity raises. The company's valuation is highly speculative, with a price-to-book ratio of 27.26, which is significantly elevated and not supported by positive earnings or cash flows. Recent events include the publication of the latest financial data, which confirms the company's continued losses and negative cash flows. No material filings or transcripts have been disclosed that would suggest a strategic pivot or significant operational change.
Key takeaways
  • CapsoVision operates with a debt-free capital structure but is burning cash at a rate of $25.19 million annually.
  • The company is unprofitable, with a net loss of $25.32 million and negative returns on equity and assets.
  • Analysts project a potential 45% upside in share price, but only two "buy" ratings have been issued.
  • The company's business model appears to be concentrated in a single product line or market, increasing vulnerability to market-specific shocks.
  • The company's valuation is speculative, with a price-to-book ratio of 27.26 that is not supported by earnings or cash flows.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$13.6M
Gross profit$7.2M
Operating income-$25.5M
Net income-$25.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$22.9M
CapEx-$90.0k
Free cash flow-$25.2M
Total assets$18.2M
Total liabilities$4.9M
Total equity$13.3M
Cash & equivalents
Long-term debt$0.00
Valuation
Market price$7.25
Market cap$361.4M
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B27.3
P/Tangible book27.3
Tangible book$13.3M
Net cash
Current ratio3.8
Debt/Equity0.0
ROA-1.4%
ROE-1.9%
Cash conversion90.0%
CapEx/Revenue-0.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricCVActivity
Op margin-188.3%-16.5% medp25 -174.5% · p75 8.8%bottom quartile
Net margin-186.8%-16.5% medp25 -172.4% · p75 8.4%bottom quartile
Gross margin52.9%47.4% medp25 34.2% · p75 65.3%above median
CapEx / revenue-0.7%-5.4% medp25 -12.5% · p75 -2.2%top quartile
Debt / equity0.0%4.3% medp25 0.0% · p75 28.0%bottom quartile
Observations
IR observations
Mean price target10.50 USD
Median price target10.50 USD
High price target11.00 USD
Low price target10.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.48 USD
Last actual EPS-1.03 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 21:25 UTC#96c4f282
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:40 UTCJob: 3eb0d4aa